tiprankstipranks
Advertisement
Advertisement
Beyond Air announces termination of NeuroNOS agreement with XTL
PremiumThe FlyBeyond Air announces termination of NeuroNOS agreement with XTL
28d ago
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
Premium
Company Announcements
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
1M ago
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
Premium
The Fly
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
1M ago
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
PremiumCompany AnnouncementsXTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
2M ago
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
Premium
Company Announcements
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
2M ago
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance
Premium
Company Announcements
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance
2M ago
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results
PremiumCompany AnnouncementsXTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results
3M ago
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance
Premium
Company Announcements
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance
3M ago
XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary
Premium
Company Announcements
XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100